<DOC>
	<DOCNO>NCT00729209</DOCNO>
	<brief_summary>This Phase 1 study , involve 29-day treatment period , design evaluate pharmacokinetics effectiveness investigational study drug ARRY-371797 treating rheumatoid arthritis patient receive stable dos methotrexate , evaluate drug 's safety . Approximately 30 patient US enrol study .</brief_summary>
	<brief_title>A Study ARRY-371797 Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Key Diagnosed rheumatoid arthritis ( RA ) least 3 month prior study start base upon American College Rheumatology ( ACR ) 1987 Revised Criteria . On stable weekly dose methotrexate ( MTX ) ( 10 25 mg/week inclusively ; either oral parenteral ) folate ( ≥ 5 mg weekly ) ≥ 6 week prior study start willing continue regimens duration study . Meets ACR 1991 Revised Criteria Global Functional Status RA , Class I , II , III . Completed appropriate washout period treat specified therapy . Patients may continue specify stable background therapy RA ( dose stable least 6 week prior first dose study drug , unless patient stop due document disease improvement , Sponsor approval ) . Additional criterion exist . Key Diagnosis inflammatory noninflammatory arthritis ( e.g . spondyloarthritis ; fibromyalgia , psoriatic arthritis , crystalproven gout ) may interfere disease activity assessments and/or clinically apparent osteoarthritis would affect subsequent efficacy measure . Has receive follow prior treatment : 1 . Within 4 week first dose study drug : anakinra ( Kineret® ) , etanercept ( Enbrel® ) ; 2 . Within 8 week first dose study drug : infliximab ( Remicade® ) , adalimumab ( Humira® ) , leflunomide ( Arava® ) ; 3 . At time : rituximab ( Rituxan® ) , alemtuzumab ( CamPath® ) , experimental B cell target agent . Treatment potent CYP3A inhibitor inducer , diseasemodifying antirheumatic drug ( DMARDs ) and/or biologic response modifier ( BRMs ) study . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>